File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Hepatitis B surfact antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapy

TitleHepatitis B surfact antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapy
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2012
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
The 2012 Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand, 5–8 December 2012. In Journal of Gastroenterology and Hepatology, 2012, v. 27 suppl. S5, p. 257, abstract P11-162 How to Cite?
AbstractBACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual HBsAg decline when comparing baseline HBeAg-positive and negative patients (0.111 and 0.064 log IU/ mL/year respectively, p = 0.165), genotypes B and C (0.081 and 0.125 log IU/mL/year respectively, p = 0.170), and persistent undetectable viremia versus intermediate levels of viremia of 20–2000 IU/mL (0.081 and 0.124 log IU/mL/year respectively, p = 0.232).7 patients (9.6% 4 HBeAg-positive and 3 HBeAg-negative) achieved HBsAg seroclearance after a median period of 7.59 (range 3.59 to 12.15) years. The 7 patients achieving HBsAg seroclearance, when compared to the remaining 64 patients, had a lower median baseline HBsAg level (2.72 and 3.67 log IU/mL respectively, p = 0.029) and a significantly larger HBsAg decline (0.401 log IU/mL/year versus 0.081 log IU/mL respectively, p < 0.001) CONCLUSION: HBsAg reduction remained relatively stable during long-term lamivudine therapy. A low baseline HBsAg level and an increased HBsAg decline rate would be a pre-requisite for subsequent HBsAg seroclearance.
DescriptionThis journal suppl. entatiled: Special Issue: Asian Pacific Digestive Week 2012 ...
Poster Presentation 11. Liver: no. P11-162
Persistent Identifierhttp://hdl.handle.net/10722/186845
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2013-08-20T12:21:13Z-
dc.date.available2013-08-20T12:21:13Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 Asian Pacific Digestive Week (APDW 2012), Bangkok, Thailand, 5–8 December 2012. In Journal of Gastroenterology and Hepatology, 2012, v. 27 suppl. S5, p. 257, abstract P11-162en_US
dc.identifier.issn0815-9319-
dc.identifier.urihttp://hdl.handle.net/10722/186845-
dc.descriptionThis journal suppl. entatiled: Special Issue: Asian Pacific Digestive Week 2012 ...-
dc.descriptionPoster Presentation 11. Liver: no. P11-162-
dc.description.abstractBACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual HBsAg decline when comparing baseline HBeAg-positive and negative patients (0.111 and 0.064 log IU/ mL/year respectively, p = 0.165), genotypes B and C (0.081 and 0.125 log IU/mL/year respectively, p = 0.170), and persistent undetectable viremia versus intermediate levels of viremia of 20–2000 IU/mL (0.081 and 0.124 log IU/mL/year respectively, p = 0.232).7 patients (9.6% 4 HBeAg-positive and 3 HBeAg-negative) achieved HBsAg seroclearance after a median period of 7.59 (range 3.59 to 12.15) years. The 7 patients achieving HBsAg seroclearance, when compared to the remaining 64 patients, had a lower median baseline HBsAg level (2.72 and 3.67 log IU/mL respectively, p = 0.029) and a significantly larger HBsAg decline (0.401 log IU/mL/year versus 0.081 log IU/mL respectively, p < 0.001) CONCLUSION: HBsAg reduction remained relatively stable during long-term lamivudine therapy. A low baseline HBsAg level and an increased HBsAg decline rate would be a pre-requisite for subsequent HBsAg seroclearance.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleHepatitis B surfact antigen kinetics during 10 years of virologic suppression with nucleoside analogue therapyen_US
dc.typeConference_Paperen_US
dc.identifier.emailSeto, WK: wkseto2@hku.hken_US
dc.identifier.emailWong, DKH: danywong@hku.hken_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WK=rp01659en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/jgh.12006-
dc.identifier.hkuros220782en_US
dc.identifier.volume27en_US
dc.identifier.issuesuppl. S5en_US
dc.identifier.spage257en_US
dc.identifier.epage257en_US
dc.publisher.placeAustralia-
dc.customcontrol.immutablesml 130903-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats